Should INSTI- or TAF-Related Weight Gain Prompt a Switch?

Roughly 15% of people living with HIV gain more than 10% of their body weight in the first one to two years of treatment with an integrase strand transfer inhibitor (INSTI) or tenofovir alafenamide (TAF) regimen, leaving clinicians with the clinical question of whether to switch to a non-INSTI or non-TAF regimen. The answer is unclear, experts said.